Literature DB >> 3094204

Inactivation of human T-cell lymphotropic virus, type III by heat, chemicals, and irradiation.

G V Quinnan, M A Wells, A E Wittek, M A Phelan, R E Mayner, S Feinstone, R H Purcell, J S Epstein.   

Abstract

Infectivity of human T-cell lymphotropic virus, Type III (HTLV-III) was inactivated by heat more rapidly if in liquid medium than if lyophilized and more rapidly at 60 degrees than 56 degrees C. When HTLV-III was added to factor VIII suspension, then lyophilized and heated at 60 degrees C for 2 hours or longer there was elimination of 1 X 10(6) in vitro infectious units (IVIU) of virus. Much of the viral inactivation appeared to result from lyophilization. The application of water-saturated chloroform to the lyophilized material containing virus also resulted in elimination of infectivity. HTLV-III was efficiently inactivated by formalin, beta-propiolactone, ethyl ether, detergent, and ultraviolet light plus psoralen. The results are reassuring regarding the potential safety of various biological products.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3094204     DOI: 10.1046/j.1537-2995.1986.26587020131.x

Source DB:  PubMed          Journal:  Transfusion        ISSN: 0041-1132            Impact factor:   3.157


  9 in total

Review 1.  Viral contamination of monoclonal antibody preparations: potential problems and possible solutions.

Authors:  C Harbour; G Woodhouse
Journal:  Cytotechnology       Date:  1990-07       Impact factor: 2.058

2.  HIV transmission to patients with hemophilia by heat-treated, donor-screened factor concentrate.

Authors:  R S Remis; M V O'Shaughnessy; C Tsoukas; G H Growe; M T Schechter; R W Palmer; D N Lawrence
Journal:  CMAJ       Date:  1990-06-01       Impact factor: 8.262

3.  Detection and characterization of porcine endogenous retrovirus in porcine plasma and porcine factor VIII.

Authors:  D M Takefman; S Wong; T Maudru; K Peden; C A Wilson
Journal:  J Virol       Date:  2001-05       Impact factor: 5.103

4.  Enhanced binding of antibodies to neutralization epitopes following thermal and chemical inactivation of human immunodeficiency virus type 1.

Authors:  K Grovit-Ferbas; J F Hsu; J Ferbas; V Gudeman; I S Chen
Journal:  J Virol       Date:  2000-07       Impact factor: 5.103

5.  Inactivation of human immunodeficiency virus in serum specimens as a safety measure for diagnostic immunoassays.

Authors:  P Ukkonen; J Korpela; J Suni; K Hedman
Journal:  Eur J Clin Microbiol Infect Dis       Date:  1988-08       Impact factor: 3.267

6.  Infection control revisited: dilemma facing today's bronchoscopists.

Authors:  P J Hanson; D J Jeffries; J C Batten; J V Collins
Journal:  BMJ       Date:  1988-07-16

7.  Construction and characterization of a full-length infectious simian T-cell lymphotropic virus type 3 molecular clone.

Authors:  Sébastien Alain Chevalier; Marine Walic; Sara Calattini; Adeline Mallet; Marie-Christine Prévost; Antoine Gessain; Renaud Mahieux
Journal:  J Virol       Date:  2007-04-11       Impact factor: 5.103

8.  Double cryoprecipitated factor VIII concentrate from heparinised plasma and its heat treatment.

Authors:  C T Smit Sibinga; P J Schulting; J Notebomer; P C Das; J Marrink; J vd Meer
Journal:  Blut       Date:  1988-03

9.  Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.

Authors:  Perrine Courlet; Susana Alves Saldanha; Matthias Cavassini; Catia Marzolini; Eva Choong; Chantal Csajka; Huldrych F Günthard; Pascal André; Thierry Buclin; Vincent Desfontaine; Laurent Arthur Decosterd
Journal:  J Mass Spectrom       Date:  2020-03-11       Impact factor: 1.982

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.